VitaDX launches today its first clinical trial VisioCyt 1. This multicentric study on 1300 patients aims to evaluate the diagnostic performances of the VisioCyt® test.
Thursday January 5th, 2017
Tuesday December 20th, 2016
VitaDX is one of the top 100 medical technology startups, according to Innovation Review magazine.
Wednesday November 23rd, 2016
VitaDX and EVOSCIENCES enter into a partnership to facilitate access to the equipment required for the implementation of the VisioCyt® solution.
Monday November 21st, 2016
The startup is officially starting its second round of fundraising of 1.5 M€ due in the first quarter of 2017 to support the development of its non-invasive medical device.